Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Int J Biol Sci. 2024 Oct 21;20(14):5747-5763. doi: 10.7150/ijbs.100960. eCollection 2024.
Bone metastasis is a common cause of death in patients with non-small cell lung cancer (NSCLC), with approximately 30-40% of NSCLC patients eventually developing bone metastases. Bone metastasis, especially the occurrence of skeletal-related events (SREs), significantly reduces overall survival (OS) and quality of life (QoL) in patients. Although bone-targeting agents (BTAs) have been shown to reduce SREs and improve QoL in NSCLC patients with bone metastases, the prognosis for these patients remains poor. Understanding the underlying molecular pathways of bone metastasis is crucial for the development of novel therapeutic approaches. Bone metastasis is a complex, multistep process that involves interactions between tumor cells and the bone microenvironment. The bone microenvironment provides a fertile soil for tumor cells, and crosstalk among various signaling pathways and secreted factors also plays a role in regulating the occurrence and progression of bone metastasis in NSCLC. In this article, we provide a comprehensive review of the process, regulatory mechanisms, and clinical treatment in NSCLC bone metastasis, with the hope of assisting with clinical treatment.
骨转移是非小细胞肺癌（NSCLC）患者死亡的常见原因，约 30-40%的 NSCLC 患者最终会发生骨转移。骨转移，特别是骨骼相关事件（SREs）的发生，显著降低了骨转移 NSCLC 患者的总生存期（OS）和生活质量（QoL）。尽管骨靶向药物（BTAs）已被证明可减少 NSCLC 骨转移患者的 SREs 并改善其 QoL，但这些患者的预后仍然较差。了解骨转移的潜在分子途径对于开发新的治疗方法至关重要。骨转移是一个复杂的多步骤过程，涉及肿瘤细胞与骨微环境之间的相互作用。骨微环境为肿瘤细胞提供了肥沃的土壤，各种信号通路和分泌因子之间的串扰也在调节 NSCLC 骨转移的发生和进展中发挥作用。本文全面综述了 NSCLC 骨转移的发生过程、调控机制和临床治疗，以期为临床治疗提供帮助。
